bpc 157 ms bpc-157 cancer risk evidence BPC-157, TB-500, and GHK-Cu: Separating Fact from Fear in Concerns BPC-157 –

nearly all efficacy evidence comes from animal or in vitro studies Fewer than 10 small human studies exist, none tracking use beyond about 12 weeks, so long-term safety (including cancer or fertility risk) is unknown Currently sits in a regulatory gray zone, complicating legitimate sourcing and quality assurance Side Effects: Most commonly reported issues are mild and short-lived: injection site soreness or reactions, occasional nausea, headache, and mild dizziness, typically resolving within hours to days

Starting with the IV after my half marathon all the way to Botox and filler

Journal of Pharmacy Practice and Research , 53(5), 677-683

Pharmacokinetic Profile Route of Administration Oral Half-Life 24h Route of Administration : Intraperitoneal injection, oral, topical Dosing Frequency : Undetermined in humans Half-Life : Not clinically established